|
The Food and Drug Administration announced on November 11, 2005, that they approved updated labeling for Johnson & Johnson's Ortho McNeil’s Ortho Evra contraceptive patch which will warn healthcare providers and patients that the product exposes women to higher levels of estrogen than most birth control pills.
Ortho Evra was the first approved contraceptive birth control patch attaches to the skin at the upper arm, buttocks, thigh, or abdomen. It was intended to be more convenient than a daily pill as the patch is replaced every week once the body depletes the estrogen and progestin contained within.
Despite the fact that the FDA has now admits that “women who use Ortho Evra are exposed to about 60 percent more estrogen than if they were taking a typical birth control pill” – important because increased estrogen means increased risks – the agency still allowed the drug on the market and at this time is unwilling to ban it.
Serious risks, which can be life threatening include:
- Blood clots
- Deep Venous Thrombosis
 Heart attacks- Hemorrhage
- Strokes
- Pulmonary Embolism
If you believe that you or a loved one has been adversely affected by Ortho Evra, please fill out an evaluation form . Provide as much information as possible to speed the processing of your inquiry.
Ricci~Leopold is here to assist you with any communication needs that will help get this important, timely information to the general public.
Please call Theodore Leopold at 800-699-1914 with any questions you may have.
|
